Figure 2.

Cost-effectiveness of biosimilar infliximab results. As shown in the figure, 83.67% of the iterations lie in the south-west quadrant (less costly and less effective) and 16.33% lie in the south-east quadrant (less costly and more effective). Those simulations that lie in the south-east quadrant imply that switching to biosimilar infliximab is a dominant strategy as it results in incremental cost-savings and an incremental gain in QALYs. The dashed line shows a decision-maker willingness to pay threshold of $50,000 which represents a maximum the decision maker may be willing to pay for one additional QALY.